- Home
- QTTB vs HRZN Comparison
QTTB vs HRZN Comparison
Compare QTTB & HRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | QTTB | HRZN |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.2M | 265.5M |
| IPO Year | 2018 | 2010 |
Fundamental Metrics
Financial Performance| Metric | QTTB | HRZN |
|---|---|---|
| Price | $8.75 | $3.73 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 6 |
| Target Price | ★ $39.67 | $4.71 |
| AVG Volume (30 Days) | 384.0K | ★ 507.8K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 19.15% |
| EPS Growth | ★ 136.78 | 62.50 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $53,737,000.00 | N/A |
| Revenue This Year | N/A | $0.10 |
| Revenue Next Year | N/A | $17.78 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.91 | $3.70 |
| 52 Week High | $23.57 | $6.78 |
Technical Indicators
Market Signals| Indicator | QTTB | HRZN |
|---|---|---|
| Relative Strength Index (RSI) | 45.29 | 31.65 |
| Support Level | $8.23 | N/A |
| Resistance Level | $9.25 | $4.75 |
| Average True Range (ATR) | 0.52 | 0.17 |
| MACD | 0.09 | -0.01 |
| Stochastic Oscillator | 34.98 | 12.44 |
Price Performance
Historical ComparisonAbout QTTB Q32 Bio Inc.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
About HRZN Horizon Technology Finance Corporation
Horizon Technology Finance Corp is a specialty finance company. Its investment objective is to maximize its investment portfolio's total return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. It lends to and invests in development-stage companies in the technology, life science, healthcare information and services, and sustainability industries.